great. Okay,
the very pleased here share company. to about pathways, Biosciences the you Summit. the with notably We're for We're most endogenous Artelo I'm minutes. signaling targeting And be over that focused much in thank stage system. novel at being Investor you a on So clinical XX therapeutics biopharmaceutical modulate next endocannabinoid able lipid-signaling to or
We making under see points traded And symbol not have some that here drug forward disclosure to the download three statements. read. course artelobio.com a our assets our where to novel a today. be just share are have We this all public of I and Artelo I'll looking about wants and main record time or One of with share folks ARTL. Biosciences we on be available pipeline, to asset, would with single in all at you to and standard our you our will ask are during development. for able filings our you key of website five
billion the we do And finished our second record market milestones and portfolio order The opportunities here in a resolve have we robust and across to sector. what we a cannabinoid estate, finally, team Artelo. have in that dollar patent the that looks and value know unique XX that that's distinct to increase like at that to We're estate Artelo a prove about leadership X, we strengthened after was development good has track this XXXX; Artelo. have a near-term X, next going over that in the patent XX, is entire months at here
of in beautiful mention wanted Now Alderley Manchester at I'm research with of coming U.K, and we'll is do international company. programs facility, these. team you But I on so to located a three deeper our The AstraZeneca an Park the the one in the the facility truly dive shores of former Jolla. from each La you to
to just a Xb/Xa nickname, we'll potency orientation mid targeting associated a It give CBX. this anorexia cancer. coupled a this the So the CBX slide, the is Phase you system, on anorexia a with here at pain for high patent receptors endocannabinoid submission think we'll main patents In an treat It's hands AstraZeneca that's was agonist. of of this in very by in there's moment. or just and receptor unique But we'll it estate, two own program, XX I pain, G a it's last year. and unpack this stage developed call ARTXX.XX, drug rather our the development protein cancer for that anorexia than in general, originally our a for that rich pending one has appropriate a more a profile And a as but issued is drug.
ARTXX.XX. University. Very nickname where system has as and upside The program, that estate proprietary endocannabinoid well multiple at program, hands anxiety but inflammation this from binding the cancer, patent filed pain rich us breast a final some an but last will inhibitor. cancers, it we IP Artelo. potential second acid at as Filed which difficulty] our last is in program, This The the including and Stony known Brook it the we as inventor originally nickname in This ARTXX.XX [technical X asset. CBD to year cocrystal is XX was as is modulator. of came XX, it's year. protein Artelo on developed patent we prostate targeting for on will
many Trademark were here out to patent of companies. were Office. clinical because by our anywhere Artelo in it's look needed rather issued inward the in on program low Patent lead a composition And sheet. the and first CBD that only than treating we XXXX, of issued COVID year the and days. outward like folks world. been have matter had has we been forward, In cocrystal a the difficult told sorting We while early had balance could We a not move U.S
so We to the from IP. anorexia worked embark recovery and We cancer legal needed our and on And regulatory to manufacturing a we study everything otherwise worked as on or we standpoint standpoint known that manufacturing. on did do the the the in the from this and as later morning probably consented data. are this patients timeframe year, update screened speak. excited an Got the Xb we And releasing in Phase and about being U.K trial. August-September very CAReS team we're a
a that's big for to folks so milestone, to. milestone a forward And look
just we all, process, about as we data. year, some the Phase recently, on I'll next would release that on this to Xa of study from program data some all submitted doing the program data to be been our full the the very program. available. randomized non-clinical we'll we time This data And as XX expect go what similar which with highlight is have CAReS the along along. on releasing press And Second XX.XX we've interesting or
of out life, with of very appetite, loss pass dive that anorexia of loss program of that diagnosis XX anorexia away a bit passed tissue real a XX stage estimated muscle, do itself. the or cancer loss anorexia. been cancer of the high journey, unmet It's I speak, life the here. cancer quickly every XX have loss which cancer unfortunately into -- of to away This Cancer out targeting X and late as from quality fatty known cachexia a of anorexia. let's this is of every a sufferers a around and need. because people eventually loss X of is X syndrome So is [indiscernible] very, Those profound
the has across specifically cancer in a there any Now to globe treat anorexia. been market, approved drug never major
standard from knowing said despite in that, of patients that there used, of sometimes family are is that And patients of or try do can year, and of ASCO the members the are no decadron in using their last corticosteroids out so be can it's Yet are no courses that patients, surprise came stimulants, in pharmacological counseling but care. that nutrition intervention physicians that and compromising. towards recommended as caregivers appetite guidelines be suffer this Short and hastening this keep anorexia death. to immuno these up May
So a this good isn't really there solution today. for
program, So what's about a entity. chemical Artelo's special Artelo synthetic new is
People or it's probably is from CBX agonist. a with THC, that's as partial receptor -- distinguished very a that the it you're This CBX, the got also are aware comes probably it with did that increased And of not soil, is I full come they're the you of the Now that out plant familiar plant, from or of earlier. came sky been chemical the associated agonist. it two probably AstraZeneca -- labs not with come a shared that potency cannabis features. One did appetite. is cannabinoid high out an
partial in Ours rather contrast is a agonist. agonist a full than
mimetics, the So put not been the mimics that THC that versions or have does the synthetic THC wasting and patient probably the the to HIV appetite, been those in of degree patients, community for. or programs and treat on have regulatory but is past of looking to community approved physician that
or peripherally drug our that is is thing second restricted. selective The
drug important sends the region in a that But So to targets with the receptors that's brain. effectively you be I just signal to share going as gut our a moment.
have into order AstraZeneca. receptors doesn't brain which appetite the in does. effectively in So go to the from This needs region, drug to is target stimulate the to gut those it data
healthy that XXX study multiple AstraZeneca pain. subjects -- XX ARTXX.XX. part every dose ascending placebo, watch was people study. pain volunteer had X and received care XX out the X every every their the was received actually This X dose as of did levels, observed a of lower received X were This of an study. in study, They drug under in a this the back different XX.XX, gain. XX, weight effect and a at XX [ph].
So drug placebo no increase gain so weight exposure had weight to those as gain. received the increased, that and did
that a so this a a and It in as Phase and at into P we be listed value underneath but if the proof a that unmet into be I a P Xb/Xa, would Phase the move phenomenal Investor phase. the P if here would we value, a going of there have much the really company, the another X.XXXX. from confidence dare company of that's lot there X.XXXX. value need Summit, only has so it's high designed footnote that the study a principle the of study, may And may the of this been -- say us gives study bottom such from was in X next prospectively is a chart, with previous
it's peripherally or that of thing second confidence this about drug that lot us Now a the is restricted. gives selective
side the picture so rhesus hand can has the there's your of monkey box a have of a It's screen, you there on And if black drug a that in see monkey. our or radio drug the XX.XX tomography up. a is imaging and PET labeled or then scan positron monkey a and tagged, nuclear on emission done lights or the had scan right
is of kind where a or heat map, more drug not. where looks it's warm or see importantly, red and cold is the like can You blue localized, is where where it's
And the system. or central or avoiding that it's you front so side if can monkey, of view top see the the from you the look down the nervous
were getting CBX the to still receptors headache different of to was that there to or high for the euphoria using give that GI plagued profile but system on us is drugs rest the target that nausea The from suffering unknown, So was and or somnolence, target placebo. gain stimulate but anorexia. the they of appreciably of appetite event other this allows with weight drug, not some based agonist sacrificing off whether endocannabinoid the a upon and effects some people has mild than without CBX, adverse target associated mild full
XX we it? We're We're study we data, Phase CAReS told a U.K. X this about the levels dose the into the portion I months of will subjects, full doing different doing all So data. XX three what this the It's that Phase the go dose are earlier months earlier. for doing Xa. from Xb the in for mentioned to pick I randomized you Xb that
U.K signed to U.K., AstraZeneca's backyard elsewhere. intention with we ex sites an team the up the not interest This in manufactured clinical this the do the trial is Our is all expressed even U.K. have in in AstraZeneca and an though
here shift our This program exciting inhibitor program. fatty very protein switch XX our at binding gears X I acid want about Artelo. and So talk program. is to
Tuckson it. people's small was the an and oncology to for the important to potential help metabolomics or endocannabinoid particular inhibitor Well, NIH But disease. or inflammation States commercialization role angiogenesis saw lipid-signaling protein a here XX next development, because lipid-signaling on work University we vascularization tumor in there the the about that causes excited see this the the tumor in one vascular drug. in really to became a pain And excited X mind an we also The and lipid-signaling United protein saw tumors $X the to is very globally, a next was developing data about the when migrate Brook binding around thing. bring exciting very as in things we for of pause about elsewhere acid was of being of gene big in so on previous billion Stony endocannabinoids and big factor, Very, main been excited this targeted does fatty Just that as of chaperones data, team experience. growth the working became with the proteomics receptors years my of and I'm I genomics, program towards nutrients system. program the the endothelial cancer. shifts. that with drug molecule experience targeting We very the I've metastatic
of validation well-known. the target this Now been has
genetically seen you there's A. effect it, that's an If [indiscernible] Chart anti-proliferative in
that lipid-signaling a higher Chart more more survival. can difficult treat. breast have vascularization, of expression feeding, or have D process. is have have so a expression it see tumor fatty Triple protein, was is is higher B, this cancer, of more protein more expressed and surprise part a one negative you growing of grade seen cancers rapidly nutrients you not a more regulated or Chart of requiring breast that you over then you folks in Chart C, acid of X those that higher that that of to worse If that have which tumor binding up
yes. prostate is question answer inhibitor, highly at University preclinical cancer. platform real can the example, then was in the So And models take castration put the made and Brook the metastatic Stony of for you that models is that resistant, -- of
the that from given seem today can to days generation which You were that behold, compared and or protection. mice University those drug Genentech XX Roche data not ARTXX.XX. of have the a And exciting. and growth were drug the over published seeing study took even we're stony like those sure against versus our it that recapitulate And inhibitors control from tumor given data has in -- the were mice this a That's seen with the than Brook's Liverpool, agent to the much of less I'm was and data from that very [indiscernible] had vast this activity here the knockout unprotected inhibitor. mice support single no that first its
care, in of side combinations we but is So would often know limit end taxanes Stony that long-term that utility use. its -- cancer or will in the often exhaust cancer either used they are with agent, Brook they'll single effects said, standard up some treatments and its often well, that's but good,
And prostate high inhibitors. we second versus, with and lines that different I'm taxanes cell synergistic added dose be cell XXXX. happen both our low that hat say, was generation so of to to lines in high alone. the and in pleased taxanes let's there -- to would what superior in three inhibitors taxanes dose of added use report would And protein binding across acid data it inhibitor that like X with if published three docetaxel, all was dose inhibition two fatty cancer to
cancer. at that the of the to Stony NCI prostate this advance backs our Brook in partner grants that of million the $X.X on program So
So to next have in of that We're where we going are with this? the at clinic aiming end the year.
our proprietary Finally, quickly I cocrystal. CBD:TMP mention did want to
advantages of build get drug, if estate. three that have our to unfair advantages means That and to past in the need, diseases, has should XX, have in a the big So patent wants in That it this through our large unmet unfair December to particular a patent we there's significant we diseases program. market, CBD violate are exploit where PTSD. protection with The diseases, XXXX. development somebody where gives lot would onto generic such they for challenged orphan rare drug not just chance us in a as been but and is that
it solid variety less drugs plague we polymorphism. that's no second longer is uniformity in polymorphism The exposure shapes has exploit unfair the or more advantage and or or have its that different we that And that or stability. its so that biodistribution
as that polymorphism. And so we were last least, able to take Asia, this doses and Europe be extract. form it's a agent of preclinical evidence to with a also but cocrystal known And in coffee PTSD. in is flavoring, models to food a high has is Tetramethylpyrazine, in combine plant a as as It but In it's used high, this eliminate we which not single another neuroprotective.
cocrystals. combination, to clinical bear that CBD, with winning Entresto, a little By we table. you of space cannabinoid our think new have to which to the PTSD, will combine introduction bit is and Its data that Artelo. the that's cocrystals by company. out. pharma, are A when not It's used about we So, sufferers really cap Lexapro, way, new of also have the
it's of have We say from million warrants that Since have million. been in XX last $XX.X there have last shares exercised, excess today. and That reported been so shares issued was forma safe reported issued and pro have outstanding. cash filing. our we XX.X of that reported then some our Q We -- outstanding north to million
is filing the of Our April. next middle Q
no debt or ATM. line equity We have
would you time, of happy some we to is either. bios had of more the offering accomplishments are that We would the team our with website. have if whose on share significant -- be I a team
management, the of leadership oversight the Board from On the are collaborators. Directors scientific
amplifies of portfolio and minutes I've to assets robust So company, of Artelo. estate it here at that risks convince all assets that the strengthened a mitigates to have last I was entire XX that ups patent across year. have a been in very upside and but novel this each have A opportunity you one drug drug hope the able we our these three pipeline could the last been
with I milestones we expect think shared the portfolio. you near-term that I've our with
going the a that, including With team that I'd I our want leadership Summit we're there agenda. your website. questions after and for dollar our Thank the any Artelo are Investor you in invite of market you. again, markets you Biosciences All billion to to that to ask opportunities thank like I to would if moderator go and
